Pinteon Therapeutics, Inc   Report issue

For profit Phase 1
Founded: Boston MA United States (2014)

Organization Overview

First Clinical Trial
2019
NCT04096287
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Pinteon Therapeutics | Pinteon Therapeutics, Inc

Active Ingredients

Drugs in Phase 1 Trials (2)

dextrose (1 trial)

pnt001 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Injuries (Phase 1)

Brain Injuries, Traumatic (Phase 1)

Wounds and Injuries (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2